Literature DB >> 21983945

Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C.

Lucy Golden-Mason1, Kiran M Bambha, Linling Cheng, Charles D Howell, Milton W Taylor, Paul J Clark, Nezam Afdhal, Hugo R Rosen.   

Abstract

UNLABELLED: Natural killer (NK) cells constitute a first line of defense against viral infections; their function is governed by the integration of signals from multiple activating and inhibitory surface receptors. We hypothesized that because NKs become rapidly activated by cytokines, response to anti-hepatitis C virus (HCV) therapy would be predicted by the phenotype and function of NKs. We used a cohort of 101 patients (55 African, 46 Caucasian-American) who received pegylated-interferon (IFN) and ribavirin for 48 weeks. Multiparameter FACS analysis was used to examine relative expression of 14 different inhibitory/activating receptors. Interleukin (IL)-28B genotyping (rs12979860) was also performed. Pretreatment levels of inhibitory receptors CD158a, CD158b, and CD158e were higher in patients who demonstrated poor viral decline within the first 28 days of therapy. Higher expression levels of inhibitory receptors NKG2A, CD158b, and CD158e were demonstrable in patients who failed to achieve sustained virologic response (SVR). Patients carrying the IL-28B T allele had higher NKG2A expression on effector NKs. We created a mathematical regression model incorporating race, viral level, and two inhibitory receptors. The area-under-the curve was 0.88, which is highly predictive of SVR. Moreover, the model performed complementarily with IL-28B across the CC, CT, and TT genotypes. Purified NKG2A(neg) NKs treated with pegylated-IFN-α for 4 hours demonstrated higher levels of IFN-γ-inducible protein-10 (IP-10) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) compared with their NKG2A(pos) counterparts.
CONCLUSIONS: These results provide novel insights into the associations of NK phenotype with IL-28B genotype and gene expression patterns, as well as the role of NKs in mediating IFN-induced viral clearance of chronic HCV infection.
Copyright © 2011 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21983945      PMCID: PMC3206734          DOI: 10.1002/hep.24556

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  26 in total

Review 1.  Peginterferon and ribavirin for chronic hepatitis C.

Authors:  Jay H Hoofnagle; Leonard B Seeff
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

2.  Racial differences in response to interferon-based antiviral therapy for hepatitis C virus infection: a hardwiring issue?

Authors:  Andrew W Tai; Raymond T Chung
Journal:  J Infect Dis       Date:  2009-04-15       Impact factor: 5.226

3.  Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

Authors:  Hari S Conjeevaram; Michael W Fried; Lennox J Jeffers; Norah A Terrault; Thelma E Wiley-Lucas; Nezam Afdhal; Robert S Brown; Steven H Belle; Jay H Hoofnagle; David E Kleiner; Charles D Howell
Journal:  Gastroenterology       Date:  2006-08       Impact factor: 22.682

4.  Projecting future complications of chronic hepatitis C in the United States.

Authors:  Gary L Davis; James E Albright; Suzanne F Cook; Daniel M Rosenberg
Journal:  Liver Transpl       Date:  2003-04       Impact factor: 5.799

5.  Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy.

Authors:  Milton W Taylor; Takuma Tsukahara; Leonid Brodsky; Joel Schaley; Corneliu Sanda; Matthew J Stephens; Jeanette N McClintick; Howard J Edenberg; Lang Li; John E Tavis; Charles Howell; Steven H Belle
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

6.  Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection.

Authors:  Megan M Dring; Maria H Morrison; Brian P McSharry; Kieran J Guinan; Richard Hagan; Cliona O'Farrelly; Clair M Gardiner
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-14       Impact factor: 11.205

Review 7.  Natural killer cells: primary target for hepatitis C virus immune evasion strategies?

Authors:  Lucy Golden-Mason; Hugo R Rosen
Journal:  Liver Transpl       Date:  2006-03       Impact factor: 5.799

8.  Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy.

Authors:  Maureen J Donlin; Nathan A Cannon; Ermei Yao; Jia Li; Abdus Wahed; Milton W Taylor; Steven H Belle; Adrian M Di Bisceglie; Rajeev Aurora; John E Tavis
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

9.  Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients.

Authors:  Marija Zeremski; Marianthi Markatou; Queenie B Brown; Gary Dorante; Susanna Cunningham-Rundles; Andrew H Talal
Journal:  J Acquir Immune Defic Syndr       Date:  2007-07-01       Impact factor: 3.731

Review 10.  Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man.

Authors:  David G Bowen; Christopher M Walker
Journal:  J Exp Med       Date:  2005-06-06       Impact factor: 14.307

View more
  29 in total

Review 1.  Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells.

Authors:  Barbara Rehermann
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

2.  Phenotypic characteristics of natural killer cells in acute hepatitis.

Authors:  Hyosun Cho
Journal:  J Microbiol       Date:  2013-04-27       Impact factor: 3.422

Review 3.  Individualization of chronic hepatitis C treatment according to the host characteristics.

Authors:  Nikolaos K Gatselis; Kalliopi Zachou; Asterios Saitis; Maria Samara; George N Dalekos
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

4.  Higher expression of inhibitory CD158b and CD158e NK cell receptor and age predicts treatment response in children with chronic hepatitis C.

Authors:  Anna Mania; Mariusz Kaczmarek; Paweł Kemnitz; Katarzyna Mazur-Melewska; Magdalena Figlerowicz; Jan Sikora; Wojciech Służewski; Jan Żeromski
Journal:  Med Microbiol Immunol       Date:  2017-11-08       Impact factor: 3.402

5.  Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα.

Authors:  Elisavet Serti; Heiyoung Park; Meghan Keane; Ashley C O'Keefe; Elenita Rivera; T Jake Liang; Marc Ghany; Barbara Rehermann
Journal:  Gut       Date:  2016-01-04       Impact factor: 23.059

6.  Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.

Authors:  Rikke Olesen; Selena Vigano; Thomas A Rasmussen; Ole S Søgaard; Zhengyu Ouyang; Maria Buzon; Arman Bashirova; Mary Carrington; Sarah Palmer; Christel R Brinkmann; Xu G Yu; Lars Østergaard; Martin Tolstrup; Mathias Lichterfeld
Journal:  J Virol       Date:  2015-07-29       Impact factor: 5.103

7.  Alterations in NK cell phenotype in relation to liver steatosis in children with chronic hepatitis C.

Authors:  Anna Mania; Mariusz Kaczmarek; Paweł Kemnitz; Iwona Mozer-Lisewska; Jan Sikora; Magdalena Figlerowicz; Aldona Woźniak; Katarzyna Mazur-Melewska; Wojciech Służewski; Jan Żeromski
Journal:  Inflammation       Date:  2013-10       Impact factor: 4.092

8.  Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.

Authors:  Susanna Naggie; Anu Osinusi; Antonios Katsounas; Richard Lempicki; Eva Herrmann; Alexander J Thompson; Paul J Clark; Keyur Patel; Andrew J Muir; John G McHutchison; Joerg F Schlaak; Martin Trippler; Bhavana Shivakumar; Henry Masur; Michael A Polis; Shyam Kottilil
Journal:  Hepatology       Date:  2012-07-02       Impact factor: 17.425

Review 9.  NK cells and virus-related cancers.

Authors:  Rabinarayan Mishra; Raymond Welsh; Eva Szomolanyi-Tsuda
Journal:  Crit Rev Oncog       Date:  2014

Review 10.  Immunopathogenesis of Hepatitis C Virus Infection.

Authors:  David E Kaplan
Journal:  Gastroenterol Clin North Am       Date:  2015-08-13       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.